

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/593,502
				Filing Date	November 9, 2007
				First Named Inventor	John A. Porco, Jr.
				Art Unit	1625
				Examiner Name	Chandrakumar, N.
Sheet	1	of	5	Attorney Docket Number	0079571-0110

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	US 6,099,751	08-08-2000	MEYER et al.	
	A2	US 5,169,943	12-08-1992	LUBINEAU et al.	
	A3	US 2008-0177093 A1	07-24-2008	JONES et al.	
	A4	US 2009-0299081 A1	12-03-2009	PORCO	
	A5	60/802,560	05-22-2006	PORCO	
	A6	60/555,448	03-23-2004	PORCO et al.	
	A7	60/612,009	09-22-2004	PORCO et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
	B1	WO-2005/092876	10-06-2005	TRUSTEES OF BOSTON UNIVERSITY		
	B2	WO 2007/139749	12-06-2007	TRUSTEES OF BOSTON UNIVERSITY		
	B3					
	B4					
	B5					

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with a single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	ADEMBRI <i>et al.</i> , "Influence of the solvent on the stereoselectivity of 1,3-dipolar cycloaddition of nitrile oxides on several 4-substituted 2-cyclopentenones," <i>J. Chem. Res.</i> 2003(3):126-127 (2003).	
	C2	ALTAVA <i>et al.</i> , "On the origin of changes in topicity observed in Diels–Alder reactions catalyzed by Ti–TADDOLates," <i>Tetrahedron: Asymmetry</i> 11(24):4885–4893 (2000).	
	C3	BADER <i>et al.</i> , "Proton transfer in 3-hydroxylavone studied by high-resolution 10 K laser-excited Shpol'skii spectroscopy," <i>J. Phys. Chem. A.</i> 106:2844–2849 (2002)	
	C4	BAUER <i>et al.</i> , "Catalytic enantioselective reactions driven by photoinduced electron transfer," <i>Nature</i> 436:1139–1140 (2005).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/593,502	
			Filing Date	November 9, 2007	
			First Named Inventor	John A. Porco, Jr.	
			Art Unit	1625	
			Examiner Name	Chandrakumar, N.	
Sheet	2	of	5	Attorney Docket Number	0079571-0110

C5	BECK <i>et al.</i> , "Grossansätze zur Herstellung von $\alpha,\alpha,\alpha^1,\alpha^1$ -Tetraaryl-1,3-dioxolan-4,5-dimethanolen (TADDOLe): Nützliche Hilfsstoffe für die EPC-Synthese und ihre Struktur im Festkörper," <i>Chimia</i> 45:238-244 (1991).
C6	BHASKER GONDI <i>et al.</i> , "Hydrogen Bond Catalyzed Enantioselective Vinylogous Mukaiyama Aldol Reaction," <i>Org. Lett.</i> 7(25):5657-5660 (2005).
C7	BRADER <i>et al.</i> , "Bisamides, lignans, triterpenes, and insecticidal Cyclopenta[b]benzofurans from <i>Aglaia</i> species," <i>J. Nat. Prod.</i> 61:1482-1490 (1998).
C8	BURKE, "Targeting IkappaB kinase for the treatment of inflammatory and other disorders," <i>Curr. Opin. Drug Discov. Devel.</i> 6:720-728 (2003).
C9	CHADIR <i>et al.</i> , "New Insecticidal Rocaglamide Derivatives from Flowers of <i>Aglaia Duperreana</i> (Meliaceae)," <i>Phytochemistry</i> 52:837-842 (1999).
C10	CUENCA <i>et al.</i> , "Highly enantioselective protonation of the 3,4-dihydro-2-methylnaphthalen-1(2H)-one Li-enolate by TADDOLs," <i>Helv. Chim. Acta</i> 83:3153-3162 (2000).
C11	CUI <i>et al.</i> , "Novel Cytotoxic 1H-Cyclopenta[b]Benzofuran Lignans from <i>Aglaia Elliptica</i> ," <i>Tetrahedron</i> 53:17625-17632 (1997).
C12	DAS <i>et al.</i> , "A critical role for NF-kappa B in GATA3 expression and TH2 differentiation in allergic airway inflammation," <i>Nature Immunol.</i> 2:45-50 (2001).
C13	DEMCHENKO, "Elimination of the Hydrogen Bonding Effect on the Solvatochromism of 3-Hydroxyflavones" <i>J. Phys. Chem. A</i> 107:4211-4216 (2003).
C14	DIEDRICHS <i>et al.</i> , "A Highly Efficient Synthesis of Rocaglaols by a Novel $\alpha$ -Arylation of Ketones," <i>Eur J. Org. Chem.</i> 9:1731-1735 (2005).
C15	DUMONTET <i>et al.</i> , "New nitrogenous and aromatic derivatives from <i>Aglaia argentwa</i> and <i>A. forbesii</i> ," <i>Tetrahedron</i> 52: 6931-6942 (1996).
C16	GAGLIARDO <i>et al.</i> , "Persistent Activation of Nuclear Factor- $\kappa$ B Signaling Pathway in Severe Uncontrolled Asthma," <i>Am. J. Respir. Crit. Care Med.</i> 168:1190-1198 (2003).
C17	GARG AND AGGARWAL, "Nuclear transcription factor- $\kappa$ B as a target for cancer drug development," <i>Leukemia</i> 16:1053-1056 (2002).
C18	GERARD <i>et al.</i> , "A Biomimetic Approach to the Rocaglamides Employing Photogeneration of Oxidopyryliums Derived from 3-Hydroxyflavones," <i>J. Am. Chem. Soc.</i> 126:13620-13621 (2004).
C19	GERARD <i>et al.</i> , "Enantioselective Photocycloaddition Mediated by Chiral Brønsted Acids: Asymmetric Synthesis of the Rocaglamides," <i>J. Am. Chem. Soc.</i> 128:7754-7755 (2006).
C20	LE GOURRIERE <i>et al.</i> , "Excited State Intramolecular Proton Transfer Part 2: ESIPT to Oxygen" <i>Prog. React. Kinet.</i> 19:211-275 (1994).
C21	GREENE <i>et al.</i> , "Decarbalkoxylation of [beta]-keto esters-a new mild procedure," <i>Tetrahedron Lett.</i> 2707-2708 (1976).
C22	GROSCH <i>et al.</i> , "Highly Enantioselective Diels-Alder Reactions of a Photochemically Generated o-Quinodimethane and Olefins," <i>Angew. Chem., Int. Ed.</i> , 42:3693-3696 (2003).
C23	GUSSREGEN <i>et al.</i> , "Insecticidal rocaglamide derivatives from <i>Aglaia Duppereana</i> ," <i>Phytochemistry</i> 44:1455-1461 (1997).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/593,502	
			Filing Date	November 9, 2007	
			First Named Inventor	John A. Porco, Jr.	
			Art Unit	1625	
			Examiner Name	Chandrakumar, N.	
Sheet	3	of	5	Attorney Docket Number	0079571-0110

C24	HAILES <i>et al.</i> , "A biomimetic approach to the synthesis of rocaglamide based on a photochemical [2+2] cycloaddition of a cinnamate unit to a flavone," <i>Tetrahedron Lett.</i> , 34:5313-5316 (1993).
C25	HUANG <i>et al.</i> , "Tumor necrosis factor modulates transcription of myelin basic protein gene through nuclear factor kappa B in a human oligodendrogloma cell line," <i>Int. J. Dev. Neurosci.</i> 20:289-296 (2002).
C26	International Search Report for PCT/US2007/012062, mailed Aug. 5, 2008.
C27	International Search Report for PCT/US2005/010005, mailed Sept. 6, 2005.
C28	IRURRE <i>et al.</i> , "Synthesis and structure of (4R,5R)-à,à,à',à'-2,2-hexaphenyl-4,5-dimethanol-1,3-dioxolane," <i>Tetrahedron: Asymmetry</i> 3:1591-1596 (1992).
C29	ITO <i>et al.</i> , "Preparation and structural analysis of several new alpha, alpha, alpha'-tetraaryl-1, 3-dioxolane-4, 5-dimethanols (taddols) and taddol analogs, their evaluation as titanium ligands in the enantioselective addition of methyltitanium and diethylzinc reagent," <i>Helvetica Chim. Acta</i> 77:2071-2110 (1994).
C30	JACOBSEN, "Highly Enantioselective Thiourea-Catalyzed Nitro-Mannich Reactions" <i>Angew. Chem., Int. Ed.</i> 44:466-468 (2005).
C31	JONES <i>et al.</i> , "NF-κB as an integrator of diverse signaling pathways," <i>Cardiovasc. Toxicol.</i> 3:229-254 (2003).
C32	KALTSCHMIDT <i>et al.</i> , "Transcription factor NF-κB is activated in primary neurons by amyloid β peptides and in neurons surrounding early plaques from patients with Alzheimer disease," <i>Proc. Natl. Acad. Sci. USA</i> 94:2642-2647 (1997).
C33	KRISHNA, <i>et al.</i> , "Studies towards the synthesis of FCRR toxin: an expedition entry into 7-5-6 ring systems via [5+2] oxidopyrylium-alkene cycloaddition." <i>Tetrahedron Lett.</i> , 45 (5) (2004).
C34	LEI <i>et al.</i> , "Total synthesis of the ubiquitin-activating enzyme inhibitor (+)-panepophenanthrin," <i>Angew. Chem., Int. Ed.</i> 42:3913-3917 (2003).
C35	LEGRAND <i>et al.</i> , "Synthesis, NMR conformational studies and host-guest behaviour of new (+)-tartaric acid derivatives," <i>Tetrahedron: Asymmetry</i> 16:635-640 (2005).
C36	LIN <i>et al.</i> , "NF-κB in cancer: a marked target," <i>Semin. Cancer Biol.</i> 13:107-114 (2003).
C37	LIU <i>et al.</i> , "A general protocol for the hydroxylation of C-14 in gibberellins: synthesis of 14β-hydroxy-GA <sub>1</sub> methyl ester," <i>Tetrahedron</i> 54:11637-11650 (1998).
C38	MATTSON <i>et al.</i> , "NF-kappaB in neuronal plasticity and neurodegenerative disorders," <i>J. Clin. Invest.</i> 107:247-254 (2001).
C39	McDOUGAL <i>et al.</i> , "Asymmetric Morita-Baylis-Hillman Reactions Catalyzed by Chiral Brønsted Acids," <i>J. Am. Chem. Soc.</i> 125:12094-12095 (2003).
C40	NUGENT <i>et al.</i> , "Chiral Proton Catalysis: A Catalytic Enantioselective Direct Aza-Henry Reaction," <i>J. Am. Chem. Soc.</i> 126:3418-3419 (2004).
C41	NUGROHO <i>et al.</i> , "Insecticidal Rocaglamide Derivatives from Aglaia elliptica and A. Harmisiana," <i>Phytochemistry</i> 45:1579-1585 (1997).
C42	NUGROHO <i>et al.</i> , "An Insecticidal Rocaglamide Derivatives and Related Compounds from Aglaia Odorata (Meliaceae)," <i>Phytochemistry</i> 51:367-376 (1999).
C43	ORLOWSKI <i>et al.</i> , "NF-κB as a therapeutic target in cancer," <i>Trends Mol. Med.</i> 8:385-389 (2002).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/593,502
				Filing Date	November 9, 2007
				First Named Inventor	John A. Porco, Jr.
				Art Unit	1625
				Examiner Name	Chandrakumar, N.
Sheet	4	of	5	Attorney Docket Number	0079571-0110

C44	PAQUETTE <i>et al.</i> , "The $\alpha$ -Hydroxy Ketone ( $\alpha$ -Ketol) and Related Rearrangements" <i>Org. React.</i> 62: 477-567 (2003).
C45	PROKSCH <i>et al.</i> , "Chemistry and biological activity of rocaglamide derivatives and related compounds in <i>Aglai</i> a species (Meliaceae)," <i>Curr. Org. Chem.</i> 5:923-938 (2001).
C46	QUADRELLI <i>et al.</i> , "Intra- and Intermolecular Hydrogen Bonding Effects in Cycloadditions between Nitrile Oxides and 4-Benzoylamino-2-cyclopenten-1-ol and Its Derivatives," <i>Eur J. Org. Chem.</i> 13:2058-2065 (2002).
C47	RASTOGI <i>et al.</i> , "Intramolecular excited-state proton-transfer studies on flavones in different environments," <i>Spectrochim. Acta, Part A</i> 57:299-308 (2001).
C48	RENTZEA <i>et al.</i> , " $\alpha$ -ketol-umlagerung von myrsinol zum iso-myrsinol und mögliche biogenese des myrsinan-derüstes," <i>Tetrahedron Lett.</i> 23:1785-1788 (1982).
C49	ROSHAK <i>et al.</i> , "Small-molecule inhibitors of NF- $\kappa$ B for the treatment of inflammatory joint disease," <i>Curr. Opin. Pharmacol.</i> 2:316-321 (2002).
C50	ROSHAL <i>et al.</i> , "Flavonols and Crown-Flavonols as Metal Cation Chelators. The Different Nature of Ba <sup>2</sup> and Mg <sup>2+</sup> Complexes" <i>J. Phys. Chem.</i> 102:5907-5914 (1998).
C51	SAMANTA <i>et al.</i> , "Evidence of Ground-State Proton Transfer Reaction of 3-Hydroxyflavone in Neutral Alcoholic Solvents" <i>J. Phys. Chem. A</i> 107:6334-6339 (2003).
C52	SEEBACH <i>et al.</i> , "On the Ti-TADDOLate-Catalyzed Diels-Alder Addition of 3-Butenoyl-1,3-Oxazolidin-2-One to Cyclopentadiene. General Features of Ti-BINOLate- and Ti-TADDOLate-Mediated Reactions," <i>J. Org. Chem.</i> 60:1788 (1995).
C53	SEEBACH <i>et al.</i> , "Mixed $\beta$ -Peptides: A unique helical secondary structure in solution. Preliminary communication," <i>Helv. Chim. Acta</i> 80:2033-2038 (1997).
C54	SEEBACH <i>et al.</i> , "TADDOLs, Their Derivatives, and TADDOL Analogues: Versatile Chiral Auxiliaries," <i>Angew. Chem. Int. Ed.</i> 40:92-138 (2001).
C55	SHOELSON <i>et al.</i> , "Inflammation and the IKK beta/I $\kappa$ $\beta$ /NF- $\kappa$ $\beta$ axis in obesity- and diet-induced insulin resistance," <i>Int. J. Obes. Relat. Metab. Disord.</i> 27 (Supp. 3):S49-S52 (2003).
C56	TANAKA <i>et al.</i> , "Enantioselective [2 + 2] photodimerization reactions of coumarins in solution," <i>Org. Lett.</i> 7:1501-1503 (2005).
C57	TAYLOR <i>et al.</i> , "Asymmetric Catalysis by Chiral Hydrogen-Bond Donors" <i>Angew. Chem., Int. Ed.</i> 45:1520-1543 (2006).
C58	THADANI <i>et al.</i> , "Enantioselective Diels-Alder reactions catalyzed by hydrogen bonding," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 101:5846-5850 (2004).
C59	VALEN <i>et al.</i> , "Nuclear factor kappa-B and the heart," <i>J. Am. Coll. Cardiol.</i> 38:307-314 (2001).
C60	VAN HEEL <i>et al.</i> , "Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF- $\kappa$ B transcription factors," <i>Hum. Mol. Genet.</i> 11:1281-1289 (2002).
C61	WESSIG, "Organocatalytic Enantioselective Photoreactions" <i>Angew. Chem., Int. Ed.</i> 45:2168-2171 (2006).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/593,502
				Filing Date	November 9, 2007
				First Named Inventor	John A. Porco, Jr.
				Art Unit	1625
				Examiner Name	Chandrakumar, N.
Sheet	5	of	5	Attorney Docket Number	0079571-0110

	C62	YAMAMOTO <i>et al.</i> , "Bronsted Acid Catalysis of Achiral Enamine for Regio- and Enantioselective Nitroso Aldol Synthesis" <i>J. Am. Chem. Soc.</i> 127:1080-1081 (2005).	
	C63	YAMAMOTO <i>et al.</i> , "Role of the NF-κB Pathway in the Pathogenesis of Human Disease States," <i>Curr. Mol., Med.</i> 1:287-296 (2001).	
	C64	YAMAMOTO <i>et al.</i> , "Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer" <i>J. Clin. Invest.</i> 107:135-142 (2001).	
	C65	YANG <i>et al.</i> , "Essential Role of Nuclear Factor κB in the Induction of Eosinophilia in Allergic Airway Inflammation" <i>J. Exp. Med.</i> 188:1739-1750 (1998).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--